newsfilter
← Latest News
GlobeNewswire·

Cue Biopharma Announces Appointment of James M. Ahlers as Chief Financial Officer and CUE-221 Investigational New Drug Submission

CUE
  • Cue Biopharma (NASDAQ: CUE) appointed James M. Ahlers as Chief Financial Officer, effective August 3, 2026.
  • Mr. Ahlers will report directly to President & CEO Shao-Lee Lin, M.D., Ph.D.
  • The appointment coincides with a recent Investigational New Drug submission for CUE-221 in food allergy & an anticipated Phase 2 CSU data readout by the end of the quarter.
  • Mr. Ahlers brings over 25 years of financial leadership experience across public & private biotechnology companies.
  • Prior to Cue, he served nearly two decades as CFO of Intarcia Therapeutics & most recently worked as a consulting CFO for emerging biotechs.
  • Mr. Ahlers holds a Bachelor of Science in Accounting from the University of San Francisco.
  • The Board approved inducement equity awards including options for 51,000 shares & 25,500 restricted stock units.
  • The option exercise price is set at $30.40, based on the closing stock price on July 30, 2026.
  • Both equity awards vest over four years subject to continued employment.
  • Cue Biopharma is developing CUE-401, a lead autoimmune candidate advancing toward Phase 1, alongside its lead anti-IgE antibody in Phase 2 for allergic diseases.
  • The press release includes a cautionary note regarding forward-looking statements & risks such as the company's "going concern" status & potential clinical setbacks.